Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc EMPAVELI FDA Approval Call Transcript

May 17, 2021 / 12:00PM GMT
Release Date Price: $53.06 (+19.88%)
Operator

Good morning. My name is Catherine, and I will be your conference operator today. At this time, I would like to welcome everyone to the Apellis Pharmaceuticals conference call. For those of you participating via conference call, a slide presentation has been made available via webcast and will be posted to the Investor page of the company's website, www.apellis.com, at the conclusion of the call today. (Operator Instructions) Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Ms. Tracy Vineis, Vice President of Communications. Please proceed.

Tracy Vineis
Apellis Pharmaceuticals, Inc. - VP of Corporate Affairs

Thank you for joining us today to discuss the FDA approval of Empaveli, also known as Pegcetacoplan. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Medical Officer, Dr. Federico Grossi; Chief Commercial Officer, Adam Townsend; and Chief Financial Officer, Tim Sullivan, who will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot